News2021-05-28T14:12:08+00:00
0622, 2021

Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome

Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced today that its Phase 2b clinical trial evaluating the efficacy and safety of ecopipam (EBS-101) for the treatment [...]

063, 2021

Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award

Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award Dr. Chavala is co-founder of CiRC Biosciences with Jeff Aronin, chairman and CEO of Paragon Biosciences Chicago, June 3, 2021—CiRC Biosciences, Inc., Co-Founder and Chief Scientific Officer Sai Chavala, M.D., has been awarded the 2021 Ludwig von Sallmann Clinician-Scientist Award from the Association [...]

0323, 2021

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners Chicago, March 23, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded to develop treatments for central nervous [...]

0310, 2021

CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)

CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP) Cell Therapy Platform Seeks to Restore Vision for People with RP Chicago, March 10, 2021— CiRC Biosciences, Inc., a privately held cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for chemically induced [...]

0223, 2021

Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer

Chicago, February 23, 2021—With continued growth in its portfolio of life science companies, Paragon Biosciences announced the appointment of Jordan Dubow, M.D., as chief medical officer. Dr. Dubow is responsible for identifying and evaluating innovation opportunities utilizing his clinical and regulatory expertise and providing guidance to Paragon’s seven portfolio companies. Headquartered in Chicago, Paragon Biosciences is [...]

022, 2021

Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform

Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform Its vision restoration technology featured in Nature and New England Journal of Medicine; CiRC is Paragon’s 7 th portfolio company, with more in development Chicago, February 2, 2021 – Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies [...]

Archives
Go to Top